The content on this site is intended for healthcare professionals only
Dr Sexl speaks with ecancer at EHA 23 about findings implicating modulation of the JAK-STAT pathway in the transition of myelofibrosis to B cell lymphoma.
She describes the mixed signals of the disease transitioning from one to the other, and the existence of a hidden, amplified B cell clone which drives the aggressive lymphoma.
Dr Sexl recommends screening for this clonal population in patients eligible for JAK-STAT inhibition.
ASCO 2026: Latest updates in mRCC
Key insights from lung cancer research at ASCO 2025
ELCC 2025: Latest in EGFR positive NSCLC
New classification for identifying HR myeloma based on cytogenetic abnormalities
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
GIST tumours and soft tissue sarcomas
EAU 2024: Bladder cancer latest
